BioAtla (BCAB) Sells 9.745M Shares at $6.67
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- Wall Street set for lower open as Iran tensions jolt sentiment; chip stocks fall
- SK Hynix’s record plunge drags down global chip stocks
- Oil gains over 3% as fresh military strikes threaten Hormuz shipments
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
BioAtla Announces $65 Million Underwritten Offering of its Common Stock
November 4, 2022 9:08 AM EDTSAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it has agreed to sell 9,745,128 shares of its common stock at a price of $6.67 per share in an underwritten offering. The gross proceeds of the offering to BioAtla before deducting estimated underwriting discount and commissions and estimated offering expenses are expected to be approximately $65 million. The offering is expected to close on or about November 8, 2022, subject to the satisfaction of... More
